uPAR/PLAUR ELISA Kit, Human

Temporarily not available outside of China.The online Datasheet here is only a general version, for batch specific information please refer to the hard copy included in the product shipping package.
1/2
Price:
Size:
Number:

uPAR/PLAUR ELISA Kit, Human: General Information

Product name
uPAR/PLAUR ELISA Kit, Human
Assay type
Solid Phase Sandwich ELISA (quantitative)
Conjugate
HRP
Sample type
Serum
Sensitivity
2.32 pg/mL
Assay range
4.69-300 pg/mL
Specificity
Recognizes both recombinant and natural Human uPAR/PLAUR
Precision
  Intra-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 41.61 74.99 164.28
SD 2.49 1.70 7.97
CV(%) 6.0% 2.3% 4.9%
  Inter-assay Precision
Sample 1 2 3
N 20 20 20
Mean(pg/mL) 37.33 75.28 167.37
SD 2.65 2.84 7.47
CV(%) 7.1% 3.8% 4.5%
Recovery
The recovery of Human PLAUR spiked to different levels throughout the range of the assay in related matrices was evaluated.
Sample
serum (n=3)
Average % Recovery
89
Range
81 -97%
Linearity
Serum
  Recovery of detected
1:2 98%
1:4 110%
1:8 120%
1:16 123%
Materials provided
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
Product overview
This uPAR/PLAUR ELISA Kit, Human is an enzyme-linked immunosorbent assay for the quantitative measurement of Human uPAR/PLAUR protein in Serum . It contains recombinant Human uPAR/PLAUR, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use.
Shipping
This ELISA Kit is shipped at ambient temperature.
Storage
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA

uPAR/PLAUR ELISA Kit, Human: Images

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
This assay recognizes both recombinant and natural Human UPAR. The factors listed below were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed. Preparations of the following factors at 5 ng/mL in a mid-range recombinant human UPAR control were assayed for interference. No significant interference was observed.

uPAR/PLAUR ELISA Kit, Human: Synonyms

CD87 ELISA Kit, Human; U-PAR ELISA Kit, Human; UPAR ELISA Kit, Human; URKR ELISA Kit, Human

uPAR/PLAUR Background Information

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
Full Name
plasminogen activator, urokinase receptor
References
  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.